Order Article Reprints

Läppchen T, Bilinska A, Pilatis E, Menéndez E, Imlimthan S, Moon ES, Afshar-Oromieh A, Rösch F, Rominger A, Gourni E. Tailoring Fibroblast-Activation Protein Targeting for Theranostics: A Comparative Preclinical Evaluation of the ⁶⁸Ga- and ¹⁷⁷Lu-Labeled Monomeric and Dimeric Fibroblast-Activation Protein Inhibitors DOTA.SA.FAPi and DOTAGA.(SA.FAPi)₂. Molecules. 2024; 29(13):3093. https://doi.org/10.3390/molecules29133093

Läppchen, Tilman, Adrianna Bilinska, Eirinaios Pilatis, Elena Menéndez, Surachet Imlimthan, Euy Sung Moon, Ali Afshar-Oromieh, Frank Rösch, Axel Rominger, and Eleni Gourni. 2024. "Tailoring Fibroblast-Activation Protein Targeting for Theranostics: A Comparative Preclinical Evaluation of the ⁶⁸Ga- and ¹⁷⁷Lu-Labeled Monomeric and Dimeric Fibroblast-Activation Protein Inhibitors DOTA.SA.FAPi and DOTAGA.(SA.FAPi)₂" Molecules 29, no. 13: 3093. https://doi.org/10.3390/molecules29133093

Läppchen, T., Bilinska, A., Pilatis, E., Menéndez, E., Imlimthan, S., Moon, E. S., Afshar-Oromieh, A., Rösch, F., Rominger, A., & Gourni, E. (2024). Tailoring Fibroblast-Activation Protein Targeting for Theranostics: A Comparative Preclinical Evaluation of the ⁶⁸Ga- and ¹⁷⁷Lu-Labeled Monomeric and Dimeric Fibroblast-Activation Protein Inhibitors DOTA.SA.FAPi and DOTAGA.(SA.FAPi)₂. Molecules, 29(13), 3093. https://doi.org/10.3390/molecules29133093